| Description | Praeruptorin B is an inhibitor of sterol regulatory element-binding proteins (SREBPs). It can also significantly up-regulate CYP3A4 expression and activity via the PXR-mediated pathway. |
| In vitro | Praeruptorin B inhibits the SREBPs activity and decreases intracellular lipid levels. Praeruptorin B powerfully decreases SRE-luciferase activity in a dose-dependent manner. Praeruptorin B shows negligible cytotoxicity, even at the higher concentration. Praeruptorin B also significantly down-regulates the expression of SREBP-1c and SREBP-2 [1]. Praeruptorin B also exhibits significant inhibition on the activity of UGT1A9 [2]. |
| In vivo | The mice treated with Praeruptorin B (50 mg/kg) are significantly lighter than the vehicle-treated mice, although they are still heavier than the chow diet-fed mice. More importantly, the fat/lean and fat/body-weight ratios are obviously dropped at the same dosage of Praeruptorin B treated mice. It is also showed that the serum TC and TG levels of Praeruptorin B treated mice are significantly lower than those of the HFD-fed mice. Praeruptorin B increases HDL-c and decreases LDL-c similar to lovastatin. In addition, compared with vehicle-treated mice, Praeruptorin B significantly lowers the level of TC and TG in the liver, comparable to lovastatin. The elevated fasting blood glucose and insulin in HFD-fed mice are significantly reduced by Praeruptorin B [1]. |
| Synonyms | Praeruptorin D, (+)-川白芷内酯 |
| molecular weight | 426.46 |
| Molecular formula | C24H26O7 |
| CAS | 73069-28-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Zu-Guo Zheng, et al. Praeruptorin B improves diet-induced hyperlipidemia and alleviates insulin resistance via regulating SREBP signaling pathway. RSC Adv., 2018, 8, 354–366 2. Liu X, et al. The Inhibition of UDP-Glucuronosyltransferase (UGT) Isoforms by Praeruptorin A and B. Phytother Res. 2016 Nov;30(11):1872-1878. |